RCKT ROCKET PHARMACEUTICALS, INC.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

ROCKET PHARMACEUTICALS, INC. (RCKT) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q1 2025 earnings results disclosed via press release — full financials in the accompanying exhibit, not summarized in this filing section
• Item 2.02 filing signals formal earnings reporting event for Rocket Pharmaceuticals (RCKT), a clinical-stage gene therapy company

+1 more insights

Other ROCKET PHARMACEUTICALS, INC. 8-K Filings

8-K Mar 10, 2026

Get deeper insights on ROCKET PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.